Mitchell Sinkler & Starr PA Buys Shares of 2,360 DexCom, Inc. $DXCM

Mitchell Sinkler & Starr PA bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 2,360 shares of the medical device company’s stock, valued at approximately $206,000.

Other hedge funds have also added to or reduced their stakes in the company. Golden State Wealth Management LLC raised its stake in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after buying an additional 264 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in DexCom during the 1st quarter valued at $27,000. Anderson Financial Strategies LLC purchased a new stake in DexCom during the 1st quarter valued at $37,000. Alpine Bank Wealth Management purchased a new stake in shares of DexCom in the 1st quarter worth $40,000. Finally, Private Trust Co. NA increased its stake in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after purchasing an additional 335 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the transaction, the executive vice president owned 105,223 shares of the company’s stock, valued at $8,417,840. This represents a 1.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kyle Malady sold 667 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the transaction, the director directly owned 22,667 shares of the company’s stock, valued at $1,832,853.62. This trade represents a 2.86% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,849 shares of company stock worth $564,733. 0.32% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

DXCM has been the subject of several analyst reports. Truist Financial initiated coverage on DexCom in a research note on Monday, June 16th. They issued a “buy” rating and a $102.00 price objective for the company. Mizuho upped their price objective on DexCom from $95.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. Raymond James Financial upped their price objective on DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 31st. UBS Group upped their price objective on DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. Finally, Argus initiated coverage on DexCom in a research note on Thursday, August 21st. They issued a “buy” rating and a $100.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $97.42.

DexCom Trading Down 4.3%

Shares of DexCom stock opened at $65.12 on Friday. The company has a market capitalization of $25.54 billion, a P/E ratio of 45.22, a P/E/G ratio of 1.37 and a beta of 1.47. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The company has a fifty day moving average of $74.42 and a 200 day moving average of $77.66. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.